ArticlePloS one2017
Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 3 syntheses or guidelines pooled it, 165 citations in OpenAlex.
- Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma.British journal of cancer · 2023Pooled it
- Health system barriers influencing timely breast cancer diagnosis and treatment among women in low and middle-income Asian countries: evidence from a mixed-methods systematic review.BMC health services research · 2022Pooled it
- Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery-A systematic review and meta-analysis.Breast (Edinburgh, Scotland) · 2022Pooled it
- Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial.Annals of surgical oncology · 2025Trial
- Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population-based analysis.Cancer medicine · 2022Trial
- Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience.Breast cancer research and treatment · 2022Trial
- Long-term outcomes of invasive lobular carcinoma compared with invasive ductal carcinoma in HR-positive/HER2-negative breast cancer: a focus on luminal subtypes.Breast cancer (Tokyo, Japan) · 2026Article
- Long-term Outcomes of Slowly Proliferating Luminal A-like Invasive Lobular Carcinoma Versus Invasive Carcinoma of No Special Type.Journal of breast cancer · 2026Article
- Geographic Differences in Patient Experience After a Diagnosis of Lobular Breast Cancer.Annals of surgical oncology · 2026Article
- Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based study.ESMO open · 2026Article
- Crosstalk In: crosstalk-aware inference of tumor microenvironment cell infiltration.Journal of translational medicine · 2026Article
- Neoadjuvant versus adjuvant chemotherapy in locally advanced hormone receptor-positive, HER2-negative invasive lobular carcinoma: A retrospective cohort study based on the SEER database.Scientific reports · 2026Article
- External validation of PREDICT Breast v3.1 for overall survival in international cohorts, including young and invasive lobular subgroups.Breast cancer research and treatment · 2026Article
- A prospective single-arm pilot study evaluating [F-18]fluoroestradiol dedicated breast PET in invasive lobular carcinoma after neoadjuvant endocrine therapy.Breast cancer research : BCR · 2026Article
- Advanced models of lobular breast cancer metastasis capture clinical organ tropism, endocrine response, and bone remodeling.bioRxiv : the preprint server for biology · 2026Article
- Lobular breast cancer and prognosis: what should we tell patients?Frontiers in oncology · 2026Review
- Impact of concurrent lobular carcinoma in situ on recurrence outcomes in patients with classic and pleomorphic invasive lobular carcinoma of the breast.Breast cancer research and treatment · 2025Article
- A case of invasive lobular carcinoma, highlighting the emerging role ofRadiology case reports · 2025Article
- Retrospective insights: clinical characteristics and survival in 403 ILC cases from China.BMC cancer · 2025Article
- Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical outcomes and therapeutic strategies for infiltrating ductal carcinoma (IDC) and infiltrating lobular carcinoma (ILC) are not uniform. The primary objectives of this study were to identify the differences in the clinical characteristics and prognoses between ILC and IDC, and identify the high-risk population based on the hormone receptor status and metastasis sites. The Surveillance, Epidemiology, and End Results Program database was searched and patients diagnosed with ILC or IDC from 1990 to 2013 were identified. In total,796,335 patients were analyzed, including 85,048 withILC (10.7%) and 711,287 withIDC (89.3%). The ILC group was correlatedwith older age, larger tumor size, later stage, lower grade, metastasis disease(M1) disease, and greater counts ofpositive lymph nodesandestrogen-receptor-positive (ER)/progesterone receptor-positive (PR) positive nodes. The overall survival showed an early advantage for ILC but a worse outcome after 5 years. Regarding the disease-specific survival, the IDC cohort had advantages over the ILC group, both during the early years and long-term. In hormone status and metastasis site subgroup analyses, the ER+/PR+ subgroup had the best survival, while the ER+/PR- subgroup had the worst outcome, especially the ILC cohort. ILC and IDC had different metastasis patterns. The proportion of bone metastasis was higher in the ILC group (91.52%) than that in the IDC (76.04%), and the ILC group was more likely to have multiple metastasis sites. Survival analyses showed patients with ILC had a higher risk of liver metastasis (disease-specific survival[DSS]; P = 0.046), but had a better overall survival than the bone metastasis group (P<0.0001). We concluded that the long-term prognosis for ILC was poorer than that for IDC, and the ER+/PR- subgroup had the worst outcome. Therefore, the metastasis pattern and prognosis must be seriously evaluated, and a combination of endocrine therapy and chemotherapy should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.